Literature DB >> 30905726

Telemedicine in the Management of Exudative Age-Related Macular Degeneration within an Integrated health care System.

Matthew R Starr1, Andrew J Barkmeier1, Steven J Engman1, Anna Kitzmann1, Sophie J Bakri2.   

Abstract

PURPOSE: To investigate the outcomes of patients with exudative age-related macular degeneration (AMD) treated with intravitreal antivascular endothelial growth factors (VEGF) using a telemedicine system.
DESIGN: Interventional case series.
METHODS: This study examined all patients with exudative AMD who were receiving intravitreal anti-VEGF injections from September 1, 2015, through August 31, 2017, using electronic consultations at a single academic center and health system. Patients were managed initially by a retinal specialist and then allowed to receive further care with their local ophthalmologist. There were 200 electronic consultations placed during this time period for 83 eyes of 59 patients. Data collected included the retina specialist's recommendations: intravitreal agent, interval between injections, number of injections, and when the patient was to follow-up. All occurrences of recommendations that were not completed were reported.
RESULTS: The mean age of the patients at the time of electronic consultations was 82.3 ± 7.3 years with a mean follow-up time of 2.4 ± 0.81 years. The mean distance from the home of the patient to the retina specialist was 70 ± 44 miles. There were 14 consultations (7.1%) that did not comply with the recommendations of the retina specialist. Most of these were due to other medical comorbidities leading to missed appointments or scheduling errors.
CONCLUSIONS: In an integrated health care setting, 59 patients with exudative AMD were identified who were able to be effectively managed using a telemedicine system. In the appropriate setting, telemedicine may be able to assist in the management of patients with wet AMD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30905726     DOI: 10.1016/j.ajo.2019.03.021

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  The Impact of COVID-19 on Intravitreal Injection Compliance.

Authors:  Lauren M Wasser; Yishay Weill; Koby Brosh; Itay Magal; Michael Potter; Israel Strassman; Evgeny Gelman; Meni Koslowsky; David Zadok; Joel Hanhart
Journal:  SN Compr Clin Med       Date:  2020-10-28

2.  Hybrid Telehealth Medical Retina Clinic Due to Provider Exposure and Quarantine During COVID-19 Pandemic.

Authors:  Itay Chowers; Jaime Levy; Hamzah Aweidah; Khaled Safadi; Alan Jotkowitz
Journal:  Clin Ophthalmol       Date:  2020-10-21

Review 3.  Telemedicine for the Diagnosis and Management of Age-Related Macular Degeneration: A Review.

Authors:  Grayson W Armstrong; John B Miller
Journal:  J Clin Med       Date:  2022-02-05       Impact factor: 4.241

4.  Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study.

Authors:  Reinhard Angermann; Alexander Franchi; Katharina Frede; Victoria Stöckl; Christoph Palme; Martina Kralinger; Claus Zehetner
Journal:  BMC Ophthalmol       Date:  2022-09-19       Impact factor: 2.086

5.  Practice Patterns and Responsiveness to Simulated Common Ocular Complaints Among US Ophthalmology Centers During the COVID-19 Pandemic.

Authors:  Matthew R Starr; Rachel Israilevich; Michael Zhitnitsky; Qianqian E Cheng; Rebecca R Soares; Luv G Patel; Michael J Ammar; M Ali Khan; Yoshihiro Yonekawa; Allen C Ho; Michael N Cohen; Jayanth Sridhar; Ajay E Kuriyan
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389

Review 6.  Telemedicine in ophthalmology in view of the emerging COVID-19 outbreak.

Authors:  Adir C Sommer; Eytan Z Blumenthal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-19       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.